DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06003153

GLUCOSE-MGH

RecruitingPhase 4

GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

Assets

GLP-1 / incretin class catch-all / Semaglutide

Listed sites

1

Recruiting sites

1

Enrollment

125

estimated

Study population

Prediabetes / glucose intolerance

Key I/E criterion

—

Primary endpoint

•Insulin response to oral semaglutide treatment

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06003153
Org study ID2023P001852
Secondary IDK23DK131345

Timeline

Milestones

Study first posted2023-08-21actual
Study start2024-03-12actual
Last update posted2026-04-06actual
Primary completion2027-05-31estimated
Study completion2027-05-31estimated

Assets

Investigational agents

GLP-1 / incretin class catch-allSemaglutide

Study populations

Who this study enrolls

Prediabetes / glucose intolerance

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

1. Males or non-pregnant females

2. Ages 18-65 (inclusive)

3. Able/willing to give consent

4. Span the metabolic range between normal glycemia and pre-diabetes (fasting glucose of 100-125 mg/dL based on chart review of existing laboratory data)

Exclusion criteria

1. Currently taking medications or intending to take medications for diabetes

2. Currently taking medications or intending to take medications that affect glycemic parameters, such as glucocorticoids, growth hormone, or fluoroquinolones

3. Personal history of intestinal malabsorption, bariatric surgery, celiac disease, gallbladder disease, or pancreatitis

4. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

5. Estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 per the Modification of Diet in Renal Disease equation

6. History of cirrhosis and/or aspartate aminotransferase or alanine aminotransferase more than 3x upper limit of normal

7. Dietary restrictions preventing consumption of a MMTT

8. Women who are pregnant, nursing, or at risk of becoming pregnant

9. Participation in other interventional studies during the current study

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
3
Other (unclassified)
1

Glycemic / diabetes

3 endpoints
Primary/protocol endpoint

Insulin response to oral semaglutide treatment

Time frame:15 days

change from baseline, improvement

Secondary/protocol endpoint

Fasting glucose response to oral semaglutide treatment

Time frame:15 days

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Cumulative glucose response to oral semaglutide treatment

Time frame:15 days

Postprandial glucose

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Baseline incretin level

Time frame:120 minutes during Visit 1

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.